Puri PDRN

Puri PDRN 2.5ml x 5 is a next-generation skin revitalizing solution designed to improve elasticity, density, and deep hydration. Developed with advanced nucleic acid technology and backed by clinical studies, it combines pharmaceutical-grade Polynucleotides (PDRN, 5mg/ml) with cross-linked Hyaluronic Acid (25mg/ml) to deliver visible anti-aging and regenerative benefits.

Clinical Benefits:

• Boosts Collagen Density – Increases collagen by 42% within 16 weeks, promoting firmer, healthier skin.

• Reduces Wrinkle Depth – Minimizes vertical wrinkles by up to 57%, restoring smoother texture.

• Refines Pores – Achieves up to 39% reduction in pore size after just four sessions.

• Brightens Skin – Improves skin luminosity by 5.1%, revealing a more radiant complexion.

• Intense Hydration & Elasticity – Hyaluronic acid provides long-lasting moisture, holding up to 1000 times its weight in water.

Recommended Treatment Plan:

• Stage 1 – Hydration & Renewal: Two sessions (2-week intervals) for smoother skin and visible brightness, with 89% of users reporting improvement within 14 days.

• Stage 2 – Collagen Induction: Sessions 3–4 (3-week intervals) stimulate dermal thickening (+0.23mm on ultrasound) and enhance elasticity by 72%.

• Maintenance: Quarterly sessions maintain up to 83% of collagen gains; can be combined with Potenza RF for superior pore reduction.

Product Specifications:

• Formulation: PDRN 5mg/ml + HA 25mg/ml

• Packaging: 5 × 2.5ml sterile ampoules

• Molecular Weight: 500–1500 Da PDRN fragments

• Sterilization: Terminal sterilization at 121°C (15 minutes)

• Storage: 2–25°C, protected from light

• Shelf Life: 24 months unopened

Clinical Protocol:

• Needle: 31–34G (5/9 needle mesogun)

• Depth: 1.2–2.4mm (epidermal–dermal junction)

• Frequency: Every 2–3 weeks

• Treatment Course: 4 sessions recommended

• Dosage: 0.5–1ml per treatment area

Safety Information:

• For professional dermatological use only.

• Contraindicated in patients with active infections, pregnancy, history of keloids, or those undergoing radiation therapy.

• Mild redness may occur post-treatment and typically subsides within 24–48 hours. Discontinue if persistent hypersensitivity develops.